Chief Financial and Business Officer · 4D Molecular Therapeutics, Inc. (FDMT)

Uneek Mehra

FY2024 is the first fiscal year CompBrief holds for Uneek Mehra as a named executive officer of 4D Molecular Therapeutics; the record below is that year, complete. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2024

$823,899

Salary $545,752Stock awards $0Bonus $100,000

2nd of 3 named executive officers at 4D Molecular Therapeutics by FY2024 total.

3 named officers on file for 4D Molecular Therapeutics, FY2024

Uneek Mehra’s pay file — $29

  • 1 fiscal year of pay, line by line

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how 4D Molecular Therapeutics’s whole pay program stands against its peers

  • 4D Molecular Therapeutics’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on FDMT→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 29, 2025 (DEF 14A).

Free

Get Uneek Mehra’s full pay file as a PDF — free

More than this page: up to 10 years of Uneek’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Uneek Mehra compensation by year

4D Molecular Therapeutics Summary Compensation Table · the one fiscal year held
In US dollars, as 4D Molecular Therapeutics reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2024
Salary$545,752
Bonus$100,000
Stock awards$0
Option awards$0
Non-equity incentive$178,147
Pension and deferred compensation$0
All other$0
Total$823,899

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: 4D Molecular Therapeutics, Inc. DEF 14A filed April 29, 2025, accession 0001140361-25-016307, and prior-year filings. Open the filing on EDGAR.

How this page was built: the 4D Molecular Therapeutics, Inc. filed document, accession 0001140361-25-016307. Every figure is read from that document and cited to the page and table it appears in. Filed April 29, 2025.

Equity holdings

unvested awards at FY2024 year-end
TypeUnvested unitsValue at year-endExercise price
Option157,873—$12.02
Option56,250—$14.42

Per the Outstanding Equity Awards at Fiscal Year-End table in 4D Molecular Therapeutics, Inc.'s FY2024 proxy; value at the fiscal year-end close, as the company printed it.

4D Molecular Therapeutics’s named executive officers, FY2024

as the company reported each
Named executive officerRoleFY2024 total
David KirnChief Executive Officer$1,009,004
Uneek Mehra · this pageChief Financial and Business Officer$823,899
Fariborz KamalFormer Chief Operating Officer & President$734,607

The full 4D Molecular Therapeutics compensation record

free company brief

This page is one person within 4D Molecular Therapeutics's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are 4D Molecular Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Uneek Mehra's compensation dossier · One-time report. No refunds.